Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Hurria A, et al. Among authors: fornier m. Breast Cancer Res Treat. 2006 Aug;98(3):343-8. doi: 10.1007/s10549-006-9171-6. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541322
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. Hurria A, et al. Among authors: fornier m. J Am Geriatr Soc. 2006 Jul;54(7):1119-24. doi: 10.1111/j.1532-5415.2006.00789.x. J Am Geriatr Soc. 2006. PMID: 16866685
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Fornier MN, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C. Fornier MN, et al. Clin Cancer Res. 2007 Jan 1;13(1):223-7. doi: 10.1158/1078-0432.CCR-06-1731. Clin Cancer Res. 2007. PMID: 17200358 Clinical Trial.
Anabolic therapies for osteoporosis.
Farooki A, Fornier M, Girotra M. Farooki A, et al. Among authors: fornier m. N Engl J Med. 2007 Dec 6;357(23):2410-1. doi: 10.1056/NEJMc076405. N Engl J Med. 2007. PMID: 18057350 No abstract available.
Osteonecrosis of the jaw related to bevacizumab.
Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Estilo CL, et al. Among authors: fornier m. J Clin Oncol. 2008 Aug 20;26(24):4037-8. doi: 10.1200/JCO.2007.15.5424. J Clin Oncol. 2008. PMID: 18711196 No abstract available.
NCCN Task Force Report: Bone Health in Cancer Care.
Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. Gralow JR, et al. J Natl Compr Canc Netw. 2009 Jun;7 Suppl 3(Suppl 3):S1-32; quiz S33-5. doi: 10.6004/jnccn.2009.0076. J Natl Compr Canc Netw. 2009. PMID: 19555589 Free PMC article.
Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN. Morris PG, et al. Among authors: fornier mn. J Oral Maxillofac Surg. 2012 Dec;70(12):2768-75. doi: 10.1016/j.joms.2011.12.028. Epub 2012 Feb 11. J Oral Maxillofac Surg. 2012. PMID: 22330331
103 results